PPG To Launch PPG LINQ End-to-End Digital Solution for Global Refinish Industry
2.9.2021 14:29:00 EEST | Business Wire | Press release
PPG (NYSE: PPG) today announced that it will begin a phased launch of PPG LINQ™ – its revolutionary, new end-to-end digital solution for global automotive refinish customers.
PPG used its broad, cross-industry expertise as a global leader in automotive coatings and digital color matching technologies to develop the industry leading connectivity platform, which is designed to improve all aspects of the customer experience, partner relationships and internal body shop operations.
The first set of PPG LINQ technologies and services will start to become available beginning in early 2022 as part of a multi-year rollout. The PPG MOONWALK™ system, which is the company’s award-winning, automated paint mixing system for refinish body shops, marked the first of many customer centric innovations that fall within PPG’s digital ecosystem powered by PPG LINQ. This industry-leading system is most notably recognized for its extreme colorimetric precision, significant economic benefits and increased labor productivity.
“At PPG, we see and recognize how digital solutions are transforming customer experiences and business operations all around us,” said Chancey Hagerty, PPG vice president, global automotive refinish. “Customers demand easy, seamless digital interactions, and advances in connectivity, automation and artificial intelligence have transformed how businesses drive their operations.”
Refinish body shop customers will be able to streamline their entire repair process using the cloud-based PPG LINQ platform and its interconnected digital hardware, software and innovative services, leading to results that are more consistent and cost-effective. The PPG LINQ platform also will provide customers with the opportunity to improve the sustainability of their day-to-day operations and minimize their environmental impact with features that optimize product consumption and waste reduction. In addition, the PPG LINQ platform includes end-to-end digital tools designed to increase throughput and improve profitability by minimizing human error and increasing efficiency during the entire repair process.
PPG created the PPG LINQ platform specifically to go beyond the body shop environment to directly connect repair facilities with key industry stakeholders like distributors, manufacturers, insurance companies and end users. The platform’s streamlined body shop processes and communication tools will enable improved partner relationships with distributors, increased customer intimacy, and enhance visibility with aftermarket partners to help inform decision-making and expand business opportunities.
“Since we place our customers at the heart of everything we do, it is incredibly important to us that we enable them to be a part of our digital journey,” said Denise Lu, PPG global marketing director, global automotive refinish. “We are heavily invested in providing sustainable and technologically advanced solutions to create the body shops of tomorrow, which is a tremendous testimony to PPG’s dedication and commitment to serving our customers on a global scale.”
To learn more about PPG’s automotive refinish business, visit ppgrefinish.com.
PPG: WE PROTECT AND BEAUTIFY THE WORLD™
At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and specialty materials that our customers have trusted for more than 135 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $13.8 billion in 2020. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com.
We protect and beautify the world, MoonWalk, and PPG LINQ are trademarks and the PPG Logo is a registered trademark of PPG Industries Ohio, Inc.
CATEGORY Automotive Refinish
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005139/en/
Contact information
Gretchen Woodside
Global Automotive Refinish
724.766.5348
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
